Standard
Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors. / Spanggaard, I.; Oestrup, O.; Bertelsen, B.; Rohrberg, K. S.; de Schmidt, A. Y.; Tuxen, I. Viller; Ahlborn, L. Barlebo; Hasselby, J. Preuss; Santoni-Rugiu, E.; Marvig, R. L.; Lassen, U.; Nielsen, F. Cilius; Yde, C. Westmose; Mau-Sørensen, M.
In:
European Journal of Cancer, Vol. 103, No. Suppl. 1, 2018, p. E142-E143.
Research output: Contribution to journal › Conference abstract in journal › Research
Harvard
Spanggaard, I, Oestrup, O, Bertelsen, B, Rohrberg, KS, de Schmidt, AY, Tuxen, IV, Ahlborn, LB, Hasselby, JP, Santoni-Rugiu, E, Marvig, RL, Lassen, U, Nielsen, FC, Yde, CW & Mau-Sørensen, M 2018, 'Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors', European Journal of Cancer, vol. 103, no. Suppl. 1, pp. E142-E143.
APA
Spanggaard, I., Oestrup, O., Bertelsen, B., Rohrberg, K. S., de Schmidt, A. Y., Tuxen, I. V., Ahlborn, L. B., Hasselby, J. P., Santoni-Rugiu, E., Marvig, R. L., Lassen, U., Nielsen, F. C., Yde, C. W., & Mau-Sørensen, M. (2018). Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors. European Journal of Cancer, 103(Suppl. 1), E142-E143.
Vancouver
Spanggaard I, Oestrup O, Bertelsen B, Rohrberg KS, de Schmidt AY, Tuxen IV et al. Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors. European Journal of Cancer. 2018;103(Suppl. 1):E142-E143.
Author
Spanggaard, I. ; Oestrup, O. ; Bertelsen, B. ; Rohrberg, K. S. ; de Schmidt, A. Y. ; Tuxen, I. Viller ; Ahlborn, L. Barlebo ; Hasselby, J. Preuss ; Santoni-Rugiu, E. ; Marvig, R. L. ; Lassen, U. ; Nielsen, F. Cilius ; Yde, C. Westmose ; Mau-Sørensen, M. / Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors. In: European Journal of Cancer. 2018 ; Vol. 103, No. Suppl. 1. pp. E142-E143.
Bibtex
@article{94b9060a221645e89c5175187b94f6ef,
title = "Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors",
author = "I. Spanggaard and O. Oestrup and B. Bertelsen and Rohrberg, {K. S.} and {de Schmidt}, {A. Y.} and Tuxen, {I. Viller} and Ahlborn, {L. Barlebo} and Hasselby, {J. Preuss} and E. Santoni-Rugiu and Marvig, {R. L.} and U. Lassen and Nielsen, {F. Cilius} and Yde, {C. Westmose} and M. Mau-S{\o}rensen",
year = "2018",
language = "English",
volume = "103",
pages = "E142--E143",
journal = "European Journal of Cancer, Supplement",
issn = "0959-8049",
publisher = "Pergamon",
number = "Suppl. 1",
}
RIS
TY - ABST
T1 - Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors
AU - Spanggaard, I.
AU - Oestrup, O.
AU - Bertelsen, B.
AU - Rohrberg, K. S.
AU - de Schmidt, A. Y.
AU - Tuxen, I. Viller
AU - Ahlborn, L. Barlebo
AU - Hasselby, J. Preuss
AU - Santoni-Rugiu, E.
AU - Marvig, R. L.
AU - Lassen, U.
AU - Nielsen, F. Cilius
AU - Yde, C. Westmose
AU - Mau-Sørensen, M.
PY - 2018
Y1 - 2018
UR - https://publons.com/publon/28630236/
M3 - Conference abstract in journal
VL - 103
SP - E142-E143
JO - European Journal of Cancer, Supplement
JF - European Journal of Cancer, Supplement
SN - 0959-8049
IS - Suppl. 1
ER -
